Prasad G Iyer1, D Chamil Codipilly2, Apoorva K Chandar3, Siddharth Agarwal2, Kenneth K Wang2, Cadman L Leggett2, Laureano Rangel Latuche4, Phillip J Schulte4. 1. Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: iyer.prasad@mayo.edu. 2. Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 3. Department of Internal Medicine, Case Western Reserve University, Cleveland, Ohio. 4. Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND & AIMS: Prediction of progression risk in Barrett's esophagus (BE) may enable personalized management. We aimed to assess the adjunct value of a tissue systems pathology test (TissueCypher) performed on paraffin-embedded biopsy tissue, when added to expert pathology review in predicting incident progression, pooling individual patient-level data from multiple international studies METHODS: Demographics, clinical features, the TissueCypher risk class/score, and progression status were analyzed. Conditional logistical regression analysis was used to develop multivariable models predicting incident progression with and without the TissueCypher risk class (low, intermediate, high). Concordance (c-) statistics were calculated and compared with likelihood ratio tests to assess predictive ability of models. A risk prediction calculator integrating clinical variables and TissueCypher risk class was also developed. RESULTS: Data from 552 patients with baseline no (n = 472), indefinite (n = 32), or low-grade dysplasia (n = 48) (comprising 152 incident progressors and 400 non-progressors) were analyzed. A high-risk test class independently predicted increased risk of progression to high-grade dysplasia/adenocarcinoma (odds ratio, 6.0; 95% confidence interval, 2.9-12.0), along with expert confirmed low-grade dysplasia (odds ratio, 2.9; 95% confidence interval, 1.2-7.2). Model prediction of progression with the TissueCypher risk class incorporated was significantly superior than without, in the whole cohort (c-statistic 0.75 vs 0.68; P < .0001) and the nondysplastic BE subset (c-statistic 0.72 vs 0.63; P < .0001). Sensitivity and specificity of the high risk TissueCypher class were 38% and 94%, respectively. CONCLUSIONS: An objective tissue systems pathology test high-risk class is a strong independent predictor of incident progression in patients with BE, substantially improving progression risk prediction over clinical variables alone. Although test specificity was high, sensitivity was modest.
BACKGROUND & AIMS: Prediction of progression risk in Barrett's esophagus (BE) may enable personalized management. We aimed to assess the adjunct value of a tissue systems pathology test (TissueCypher) performed on paraffin-embedded biopsy tissue, when added to expert pathology review in predicting incident progression, pooling individual patient-level data from multiple international studies METHODS: Demographics, clinical features, the TissueCypher risk class/score, and progression status were analyzed. Conditional logistical regression analysis was used to develop multivariable models predicting incident progression with and without the TissueCypher risk class (low, intermediate, high). Concordance (c-) statistics were calculated and compared with likelihood ratio tests to assess predictive ability of models. A risk prediction calculator integrating clinical variables and TissueCypher risk class was also developed. RESULTS: Data from 552 patients with baseline no (n = 472), indefinite (n = 32), or low-grade dysplasia (n = 48) (comprising 152 incident progressors and 400 non-progressors) were analyzed. A high-risk test class independently predicted increased risk of progression to high-grade dysplasia/adenocarcinoma (odds ratio, 6.0; 95% confidence interval, 2.9-12.0), along with expert confirmed low-grade dysplasia (odds ratio, 2.9; 95% confidence interval, 1.2-7.2). Model prediction of progression with the TissueCypher risk class incorporated was significantly superior than without, in the whole cohort (c-statistic 0.75 vs 0.68; P < .0001) and the nondysplastic BE subset (c-statistic 0.72 vs 0.63; P < .0001). Sensitivity and specificity of the high risk TissueCypher class were 38% and 94%, respectively. CONCLUSIONS: An objective tissue systems pathology test high-risk class is a strong independent predictor of incident progression in patients with BE, substantially improving progression risk prediction over clinical variables alone. Although test specificity was high, sensitivity was modest.
Authors: Bashar Qumseya; Shahnaz Sultan; Paul Bain; Laith Jamil; Brian Jacobson; Sharmila Anandasabapathy; Deepak Agrawal; James L Buxbaum; Douglas S Fishman; Suryakanth R Gurudu; Terry L Jue; Sapna Kripalani; Jeffrey K Lee; Mouen A Khashab; Mariam Naveed; Nirav C Thosani; Julie Yang; John DeWitt; Sachin Wani Journal: Gastrointest Endosc Date: 2019-09 Impact factor: 9.427
Authors: Zhe Jin; Yulan Cheng; Wen Gu; Yingye Zheng; Fumiaki Sato; Yuriko Mori; Alexandru V Olaru; Bogdan C Paun; Jian Yang; Takatsugu Kan; Tetsuo Ito; James P Hamilton; Florin M Selaru; Rachana Agarwal; Stefan David; John M Abraham; Herbert C Wolfsen; Michael B Wallace; Nicholas J Shaheen; Kay Washington; Jean Wang; Marcia Irene Canto; Achyut Bhattacharyya; Mark A Nelson; Paul D Wagner; Yvonne Romero; Kenneth K Wang; Ziding Feng; Richard E Sampliner; Stephen J Meltzer Journal: Cancer Res Date: 2009-05-12 Impact factor: 12.701
Authors: Christopher Douville; Helen R Moinova; Prashanthi N Thota; Nicholas J Shaheen; Prasad G Iyer; Marcia Irene Canto; Jean S Wang; John A Dumot; Ashley Faulx; Kenneth W Kinzler; Nickolas Papadopoulos; Bert Vogelstein; Sanford D Markowitz; Chetan Bettegowda; Joseph E Willis; Amitabh Chak Journal: Gastroenterology Date: 2021-01-22 Impact factor: 22.682
Authors: Jon M Davison; John Goldblum; Udhayvir Singh Grewal; Kevin McGrath; Kenneth Fasanella; Christopher Deitrick; Aaron D DeWard; Emily A Bossart; Stephen L Hayward; Yi Zhang; Rebecca J Critchley-Thorne; Prashanthi N Thota Journal: Am J Gastroenterol Date: 2020-06 Impact factor: 12.045
Authors: S J M Hoefnagel; N Mostafavi; M R Timmer; C T Lau; S L Meijer; K K Wang; K K Krishnadath Journal: PLoS One Date: 2020-04-13 Impact factor: 3.240
Authors: Sachin Wani; Rhonda F Souza; Valerie L Durkalski; Jose Serrano; Frank Hamilton; Nicholas J Shaheen Journal: Gastroenterology Date: 2022-06-06 Impact factor: 33.883